[{"address1": "234 Church Street", "address2": "Suite 1020", "city": "New Haven", "state": "CT", "zip": "06510", "country": "United States", "phone": "203 859 3820", "website": "https://www.rallybio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.", "fullTimeEmployees": 30, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin W. MacKay Ph.D.", "age": 67, "title": "Co-Founder & Executive Chairman", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 723350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Uden M.B, M.D.", "age": 65, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 723350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan I. Lieber M.B.A.", "age": 53, "title": "CFO & Treasurer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 667134, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven W. Ryder F.A.C.P, M.D.", "age": 71, "title": "Chief Medical Officer", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 680219, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 5, "overallRisk": 6, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.71, "open": 1.71, "dayLow": 1.6, "dayHigh": 1.71, "regularMarketPreviousClose": 1.71, "regularMarketOpen": 1.71, "regularMarketDayLow": 1.6, "regularMarketDayHigh": 1.71, "beta": -1.628, "forwardPE": -1.288, "volume": 146474, "regularMarketVolume": 146474, "averageVolume": 1585087, "averageVolume10days": 218090, "averageDailyVolume10Day": 218090, "bid": 1.6, "ask": 1.63, "bidSize": 200, "askSize": 400, "marketCap": 66733372, "fiftyTwoWeekLow": 1.225, "fiftyTwoWeekHigh": 9.14, "fiftyDayAverage": 1.7587, "twoHundredDayAverage": 2.8003, "currency": "USD", "enterpriseValue": -27102632, "floatShares": 23197514, "sharesOutstanding": 41449300, "sharesShort": 1956935, "sharesShortPriorMonth": 1310415, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.047199998, "heldPercentInsiders": 0.04061, "heldPercentInstitutions": 0.75802004, "shortRatio": 0.47, "shortPercentOfFloat": 0.066199996, "impliedSharesOutstanding": 44023800, "bookValue": 2.358, "priceToBook": 0.682782, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -76275000, "trailingEps": -1.88, "forwardEps": -1.25, "enterpriseToEbitda": 0.352, "52WeekChange": -0.7464567, "SandP52WeekChange": 0.25262225, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RLYB", "underlyingSymbol": "RLYB", "shortName": "Rallybio Corporation", "longName": "Rallybio Corporation", "firstTradeDateEpochUtc": 1627565400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "49dd8bea-3b9a-369d-b66d-d25eaa1b0182", "messageBoardId": "finmb_1673028342", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.61, "targetHighPrice": 20.0, "targetLowPrice": 8.0, "targetMeanPrice": 13.0, "targetMedianPrice": 12.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 94175000, "totalCashPerShare": 2.272, "ebitda": -76899000, "totalDebt": 339000, "quickRatio": 9.337, "currentRatio": 9.77, "debtToEquity": 0.38, "returnOnAssets": -0.36803, "returnOnEquity": -0.6243, "freeCashflow": -28279124, "operatingCashflow": -56957000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-24"}]